Poor
Not Aligned
Patient Risk:
High
Summary
Substantial portions of the response are not supported by the provided prescribing information. Many claims describe oral progesterone tablets and menopause/uterine-protection uses that are absent from the label sections provided, while the label support that is present is limited to progesterone vaginal insert for ART embryo implantation/early pregnancy and selected adverse reaction/interactions/contraindications.
Category Scores
Accurate Statements
Progesterone may not be appropriate for everyone.
4 CONTRAINDICATIONS: progesterone vaginal insert should not be used in individuals with specified conditions (e.g., liver disease, known/suspected breast cancer, thromboembolism history, prior allergic reactions).
Clinicians generally consider a history of blood clots or certain cardiovascular risks when considering progesterone.
5.1 Cardiovascular or Cerebrovascular Disorders and 4 CONTRAINDICATIONS: alerts to thromboembolic disorders and discontinuation if suspected; contraindication/history of arterial or venous thromboembolism or severe thrombophlebitis.
Clinicians generally consider liver disease when considering progesterone.
4 CONTRAINDICATIONS: liver disease.
Common progesterone-related side effects can include breast tenderness.
6.2 Expected Adverse Reaction Profile and 17.2 Common Adverse Reactions: includes breast tenderness.
Common progesterone-related side effects can include mood changes.
6.2 and 17.2: includes mood swings and irritability (supports mood-related effects).
Unsupported Statements
Oral progesterone tablets are used to add or replace the hormone progesterone in people who need it.
No provided label section supports oral progesterone tablets or hormone replacement indications.
Progesterone tablets are used to treat irregular or abnormal uterine bleeding caused by low progesterone.
No provided label section supports treatment of irregular/abnormal uterine bleeding or low progesterone as an indication.
Progesterone tablets are used as hormone therapy in people who have a uterus and are using estrogen as part of menopause treatment.
No provided label section supports menopause hormone therapy/estrogen-progestin use.
In menopause hormone therapy, progesterone helps protect the uterine lining from the effects of estrogen.
No provided label section supports uterine protection/endometrial protection in menopause.
Progesterone can help stabilize the uterine lining when hormone imbalance is the cause of heavy or irregular bleeding.
No provided label section supports heavy/irregular bleeding indication or stabilization claim.
Clinicians may use progesterone to regulate bleeding patterns, especially when bleeding is linked to inadequate progesterone.
No provided label section supports regulating bleeding patterns for this purpose.
People typically take progesterone on a specific schedule based on the reason it was prescribed.
No dosage/schedule information is provided in the label sections given.
More regular bleeding patterns from progesterone can take one or more treatment cycles.
No provided label section addresses bleeding-pattern changes over treatment cycles.
Hormone-related side effects from progesterone can start soon after beginning.
No provided label section describes onset timing of side effects.
Common progesterone-related side effects can include dizziness.
Dizziness is not included in the provided adverse reaction lists.
Clinicians generally consider unexplained vaginal bleeding when considering progesterone.
No provided label section discusses unexplained vaginal bleeding as a consideration.
In menopause hormone therapy with estrogen, using progesterone alongside estrogen has a protective role of protecting the uterus from estrogen-related overgrowth.
No provided label section supports this menopause/uterine-protection concept.
Progesterone is usually timed or dosed to match the estrogen regimen in menopausal hormone therapy.
No provided label section includes menopause dosing/regimen matching.
Using estrogen without adequate uterine protection can increase risk of endometrial problems.
No provided label section discusses estrogen without uterine protection or endometrial risks.
Progesterone can be taken in different formulations, for example vaginal progesterone versus oral progesterone.
No provided label section supports oral formulation usage or contrasts oral vs vaginal.
Patients should follow the form and schedule that matches the intended medical use of progesterone.
No provided label section provides patient instructions about form/schedule selection.
Contradictions
Low
AI Statement
Progesterone tablets are used to treat irregular or abnormal uterine bleeding caused by low progesterone.
Label Reference
Provided label indication is for progesterone vaginal insert in ART to support embryo implantation/early pregnancy; no bleeding indication is provided.
Important Omissions
Dosage and administration details (dose, route, regimen, and duration) for progesterone were not provided/verified; the response asserts scheduling practices without label support.
Importance:
Moderate
Boxed warning content and pregnancy/pediatric warnings are not present in the provided label sections; the response includes serious-symptom and safety guidance that cannot be verified for these label elements.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Many key claims are not supported by the provided prescribing information, including multiple indications for oral progesterone tablets and menopause/uterine-protection uses. The label excerpt provided is specific to progesterone vaginal insert for ART embryo implantation/early pregnancy; unsupported indication/dosing-related statements could lead to misinformation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
The response repeatedly describes uses and safety/administration guidance for oral progesterone tablets and menopause estrogen-progestin uterine protection, which are absent from the provided label sections. Provided label support relates to progesterone vaginal insert for ART embryo implantation/early pregnancy and selected adverse reactions/interactions/contraindications.
Suggested Improvement
Restrict statements to the provided label-supported indication (progesterone vaginal insert for ART embryo implantation and early pregnancy), adverse reaction list (headaches, breast tenderness, bloating, mood swings/irritability, drowsiness), contraindications (allergic reactions, missed abortion/ectopic pregnancy, liver disease, known/suspected breast cancer, active/history thromboembolism/severe thrombophlebitis), and interaction principles (CYP3A4 inducers may increase elimination; avoid other vaginal products due to altered release/absorption). Avoid unverified claims about oral tablets, menopause therapy, bleeding regulation, dosing schedules, and onset timing.